晚期肝细胞癌患者的TATI综合治疗模式

doi:10.3760/cma.j.issn.1007-1245.2024.23.011

摘要/Abstract

摘要：

肝细胞癌（HCC）是常见的恶性肿瘤之一。目前，HCC的主要治疗方法包括肝移植、手术切除、各种经皮局部治疗［如经导管动脉化疗栓塞术（TACE）和消融等］，以及全身治疗［如酪氨酸激酶抑制剂（TKIs）和免疫检查点抑制剂（ICIs）等］。TATI综合治疗模式是将TACE、消融、TKIs和ICIs顺序应用于晚期HCC患者的一种新型疗法，该文通过整理分析近年晚期HCC的最新治疗进展，探索TATI综合治疗模式的可行性及安全性，以期为临床医生提供参考。

关键词:

, 肝细胞癌, 免疫检查点抑制剂, 酪氨酸激酶抑制剂, 消融, 经导管动脉化疗栓塞术, 综述

Abstract:

Hepatocellular carcinoma (HCC) is one of the common malignant tumors. Currently, the main treatment methods for HCC include liver transplantation, surgical resection, various percutaneous modalities, such as transarterial chemoembolization (TACE) and ablation, and systemic treatments, such as tyrosine kinase inhibitors (TKIs) and immune-checkpoint inhibitors (ICIs). The TATI comprehensive treatment mode is a new therapy that sequentially applies TACE, ablation, TKIs, and ICIs to patients with advanced HCC. Reviewing and analyzing the latest treatment advances for patients with advanced HCC in recent years, this article explores the feasibility and safety of the TATI comprehensive treatment mode, so as to provide references for clinical physicians.

Key words:

Hepatocellular carcinoma, Immune-checkpoint inhibitors, Tyrosine kinase inhibitors, Ablation, Transarterial chemoembolization, Survey

王山郝建斌赵杰郝延璋.

晚期肝细胞癌患者的TATI综合治疗模式 [J]. 国际医药卫生导报, 2024, 30(23): 3933-3936.

Wang Shan, Hao Jianbin, Zhao Jie, Hao Yanzhang.

TATI comprehensive treatment mode for patients with advanced hepatocellular carcinoma [J]. International Medicine and Health Guidance News, 2024, 30(23): 3933-3936.

参考文献

[1] Sung H, Ferlay J, Siegel RL,et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021,71(3):209-249.DOI: 10.3322/caac.21660.
[2] Rumgay H, Arnold M, Ferlay J,et al. Global burden of primary liver cancer in 2020 and predictions to 2040[J]. J Hepatol, 2022 ,77(6):1598-1606.DOI: 10.1016/j.jhep.2022.08.021.
[3] Singal AG, Kanwal F, Llovet JM. Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy[J]. Nat Rev Clin Oncol, 2023,20(12):864-884. DOI: 10.1038/s41571-023- 00825-3.
[4] Meng M, Li W, Yang X,et al. Transarterial chemoembolization, ablation, tyrosine kinase inhibitors, and immunotherapy (TATI): a novel treatment for patients with advanced hepatocellular carcinoma[J]. J Cancer Res Ther, 2020,16(2):327-334.DOI: 10.4103/jcrt.JCRT_101_20.
[5] Llovet JM, De Baere T, Kulik L,et al. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma[J]. Nat Rev Gastroenterol Hepatol, 2021,18(5):293-313.DOI: 10.1038/s41575-020- 00395-0.
[6] Wang L, Lin L, Zhou W. Efficacy and safety of transarterial chemoembolization combined with lenvatinib and PD-1 inhibitor in the treatment of advanced hepatocellular carcinoma: a meta-analysis[J]. Pharmacol Ther, 2024,257:108634.DOI: 10.1016/j.pharmthera.2024.108634.
[7] Cai M, Huang W, Huang J,et al. Transarterial chemoembolization combined with lenvatinib plus PD-1 inhibitor for advanced hepatocellular carcinoma: a retrospective cohort study[J]. Front Immunol, 2022,13:848387. DOI: 10.3389/fimmu.2022.848387.
[8] Palmer DH, Malagari K, Kulik LM. Role of locoregional therapies in the wake of systemic therapy[J]. J Hepatol, 2020,72(2):277-287.DOI: 10.1016/j.jhep.2019.09.023.
[9] 张国坤,张天佑,张景畅,等. 原发性肝癌患者TACE预后不良的因素分析:基于PSM法[J]. 国际医药卫生导报,2024,30(5):747-753. DOI:10.3760/cma.j.issn.1007-1245. 2024.05.009.
[10] Liu C, Li T, He JT,et al. TACE combined with microwave ablation therapy vs. TACE alone for treatment of early- and intermediate-stage hepatocellular carcinomas larger than 5 cm: a meta-analysis[J]. Diagn Interv Radiol, 2020,26(6):575-583.DOI: 10.5152/dir.2020.19615.
[11] Li Z, Li Q, Wang X,et al. Hyperthermia ablation combined with transarterial chemoembolization versus monotherapy for hepatocellular carcinoma: a systematic review and meta-analysis[J]. Cancer Med, 2021 ,10(23):8432-8450.DOI: 10.1002/cam4.4350.
[12] Ahmed M, Kumar G, Gourevitch S,et al. Radiofrequency ablation (RFA)-induced systemic tumor growth can be reduced by suppression of resultant heat shock proteins[J]. Int J Hyperthermia, 2018 ,34(7):934-942. DOI: 10.1080/02656736.2018.1462535.
[13] Chen QF, Jia ZY, Yang ZQ,et al. Transarterial chemoembolization monotherapy versus combined transarterial chemoembolization-microwave ablation therapy for hepatocellular carcinoma tumors ≤5 cm: a propensity analysis at a single center[J]. Cardiovasc Intervent Radiol, 2017 ,40(11):1748-1755.DOI: 10.1007/s00270-017-1736-8.
[14] Greten TF, Mauda-Havakuk M, Heinrich B,et al. Combined locoregional-immunotherapy for liver cancer[J]. J Hepatol, 2019 ,70(5):999-1007.DOI: 10.1016/j.jhep.2019.01.027.
[15] Llovet JM, Kelley RK, Villanueva A,et al. Author correction: hepatocellular carcinoma[J]. Nat Rev Dis Primers, 2024,10(1):10.DOI: 10.1038/s41572-024-00500-6.
[16] Zhang YL, Cui XJ, Xing H,et al. Molecular targeted therapy and immunotherapy in advanced hepatocellular carcinoma: a systematic review and bayesian network meta-analysis based on randomized controlled trials[J]. Ann Med, 2023,55(2):2242384.DOI: 10.1080/07853890.2023.2242384.
[17] Cheng AL, Qin S, Ikeda M,et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma[J]. J Hepatol, 2022,76(4):862-873.DOI: 10.1016/j.jhep.2021.11.030.
[18] Abou-Alfa GK, Chan SL, Kudo M, et al. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA[J]. Journal of Clinical Oncology, 2022, 40(4_suppl): 379-379. DOI:10.1200/JCO.2022.40.4_suppl.379.
[19] Kelley RK, Rimassa L, Cheng AL,et al. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial[J]. Lancet Oncol, 2022,23(8):995-1008. DOI: 10.1016/S1470-2045(22)00326-6.
[20] Ren Z, Xu J, Bai Y,et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study[J]. Lancet Oncol, 2021,22(7):977-990.DOI: 10.1016/S1470-2045(21)00252-7.
[21] Huinen ZR, Huijbers EJM, van Beijnum JR,et al. Anti-angiogenic agents - overcoming tumour endothelial cell anergy and improving immunotherapy outcomes[J]. Nat Rev Clin Oncol, 2021,18(8):527-540.DOI: 10.1038/s41571-021-00496-y.
[22] Fukumura D, Kloepper J, Amoozgar Z,et al. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges[J]. Nat Rev Clin Oncol, 2018,15(5):325-340.DOI: 10.1038/nrclinonc.2018.29.
[23] Ma L, Hernandez MO, Zhao Y,et al. Tumor cell biodiversity drives microenvironmental reprogramming in liver cancer[J]. Cancer Cell, 2019 ,36(4):418-430.e6.DOI: 10.1016/j.ccell.2019.08.007.
[24] Torrens L, Montironi C, Puigvehí M,et al. Immunomodulatory effects of lenvatinib plus anti-programmed cell death protein 1 in mice and rationale for patient enrichment in hepatocellular carcinoma[J]. Hepatology, 2021,74(5):2652-2669.DOI: 10.1002/hep.32023.
[25] Esteban-Fabró R, Willoughby CE, Piqué-Gili M, et al. Cabozantinib enhances the efficacy and immune modulatory activity of anti-PD1 therapy in a syngeneic mouse model of hepatocellular carcinoma[J]. Journal of Hepatology, 2020, 73(S1): S40. DOI:10.1016/s0168-8278(20)30632-2.
[26] Shigeta K, Matsui A, Kikuchi H,et al. Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma[J]. J Immunother Cancer, 2020 ,8(2):e001435. DOI: 10.1136/jitc-2020-001435.
[27] Sprinzl MF, Puschnik A, Schlitter AM,et al. Sorafenib inhibits macrophage-induced growth of hepatoma cells by interference with insulin-like growth factor-1 secretion[J]. J Hepatol, 2015,62(4):863-870. DOI: 10.1016/j.jhep.2014.11.011.
[28] Duffy AG, Ulahannan SV, Makorova-Rusher O,et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma[J]. J Hepatol, 2017 ,66(3):545-551.DOI: 10.1016/j.jhep.2016.10.029.
[29] Petrillo M, Patella F, Pesapane F,et al. Hypoxia and tumor angiogenesis in the era of hepatocellular carcinoma transarterial loco-regional treatments[J]. Future Oncol, 2018,14(28):2957-2967.DOI: 10.2217/fon-2017-0739.